Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

End-Alveolar Carbon Monoxide as a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease

NCT01547793 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT01547793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01547793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
End-Alveolar Carbon Monoxide as a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Observational
Overall status
Completed
Start date
January 26, 2012
Completion date
November 4, 2015
Enrollment
106 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, sickle cell, sickle cell anemia, sickle cell disease